Tadalafil Tablet, Film Coated
Product Images NDC 50090-8039

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-8039). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500908039)

Tadalafil 20 mg oral film-coated tablets label from A-S Medication Solutions, showing product NDC 50090-8039. The label includes storage instructions to store at 77 degrees Fahrenheit and indicates the package contains 30 tablets. A QR code for dosage instructions is also visible on the label.*

FDA Label Image

"image Description" (Tadalafil Figure 1)

A set of four line graphs showing blood pressure changes over time comparing Tadalafil to placebo. The graphs display differences in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure (mmHg) on the y-axis against time in hours on the x-axis, with error bars indicating variability.*

FDA Label Image

"image Description" (Tadalafil Figure 2)

A line graph showing systolic blood pressure changes over 24 hours post-dose for Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The upper panel depicts standing systolic blood pressure, and the lower panel depicts supine systolic blood pressure, both measured in mmHg. Trends indicate blood pressure changes relative to time after dosing.*

FDA Label Image

"image Description" (Tadalafil Figure 3)

A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg qd doxazosin, at dosing times 08:00 and 20:00. The graph compares four groups using different line styles and symbols, plotting blood pressure values against time after dosing.*

FDA Label Image

"image Description" (Tadalafil Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) versus time (hours) for three dosing regimens: single 20 mg dose, single 5 mg dose, and once-daily 5 mg dose after 5 consecutive days. Data points include error bars representing variability at each time point, illustrating pharmacokinetic profiles over 120 hours.*

FDA Label Image

"image Description" (Tadalafil Figure 5)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. Two groups are compared: Tadalafil Tablets 5 mg and placebo. The Tadalafil group shows a greater decrease in IPSS score over time than placebo, with statistical significance indicated (P < 0.01). The x-axis represents treatment duration in weeks, and the y-axis represents change in IPSS total score.*

FDA Label Image

"image Description" (Tadalafil Figure 6)

A line graph showing change from baseline in IPSS Total Score over a 12-week treatment duration comparing Tadalafil Tablets 5 mg and placebo. The vertical axis measures change in score, and the horizontal axis measures weeks. Data points indicate Tadalafil results decline more steeply than placebo, with statistical significance at certain points (P < 0.01).*

FDA Label Image

"image Description" (Tadalafil Figure 7)

Line graph showing least squares mean change from baseline over 26 weeks of therapy. The graph compares Tadalafil/Finasteride combination versus Placebo/Finasteride, with plotted values at 0, 4, 12, and 26 weeks. Statistical significance markers (p-values) are indicated for differences at certain points.*

FDA Label Image

"image Description" (Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between Tadalafil 5 mg tablets and placebo. The graph shows greater improvement with Tadalafil over time, with data points at 0, 2, 4, 8, and 12 weeks. Statistical significance is indicated at the 12-week mark.*

FDA Label Image

"image Description" (Tadalafil Structure)

Chemical structure diagram of tadalafil, the active ingredient in the product. The image shows the molecular arrangement with rings, bonds, and functional groups characteristic of tadalafil's chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.